The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.

Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.

FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.

Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.

Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.

At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.